Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics

Celldex Therapeutics Inc. (CLDX): $26.24

0.02 (-0.08%)

POWR Rating

Component Grades








Add CLDX to Watchlist
Sign Up

Industry: Biotech




#357 of 361

in industry

CLDX Price/Volume Stats

Current price $26.24 52-week high $48.40
Prev. close $26.26 52-week low $25.66
Day low $25.66 Volume 325,500
Day high $26.38 Avg. volume 509,177
50-day MA $31.28 Dividend yield N/A
200-day MA $36.82 Market Cap 1.24B

CLDX Stock Price Chart Interactive Chart >


  • Growth is the dimension where CLDX ranks best; there it ranks ahead of 24.31% of US stocks.
  • The strongest trend for CLDX is in Quality, which has been heading down over the past 179 days.
  • CLDX's current lowest rank is in the Stability metric (where it is better than 9.82% of US stocks).

CLDX Stock Summary

  • The ratio of debt to operating expenses for CELLDEX THERAPEUTICS INC is higher than it is for about merely 7.49% of US stocks.
  • CLDX's price/sales ratio is 390.72; that's higher than the P/S ratio of 98.95% of US stocks.
  • Revenue growth over the past 12 months for CELLDEX THERAPEUTICS INC comes in at 295.02%, a number that bests 97.71% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CLDX, based on their financial statements, market capitalization, and price volatility, are CRNX, FDMT, IGMS, RNA, and AEVA.
  • CLDX's SEC filings can be seen here. And to visit CELLDEX THERAPEUTICS INC's official web site, go to www.celldex.com.

CLDX Valuation Summary

  • CLDX's price/sales ratio is 390.7; this is 20463.16% higher than that of the median Healthcare stock.
  • CLDX's EV/EBIT ratio has moved up 3 over the prior 243 months.

Below are key valuation metrics over time for CLDX.

Stock Date P/S P/B P/E EV/EBIT
CLDX 2023-09-18 390.7 4.6 -11.2 -11.0
CLDX 2023-09-15 405.8 4.8 -11.7 -11.5
CLDX 2023-09-14 409.7 4.8 -11.8 -11.6
CLDX 2023-09-13 398.1 4.7 -11.5 -11.2
CLDX 2023-09-12 401.2 4.7 -11.5 -11.3
CLDX 2023-09-11 399.7 4.7 -11.5 -11.3

CLDX Growth Metrics

    Its year over year revenue growth rate is now at -22.94%.
  • Its 5 year net cashflow from operations growth rate is now at 60.06%.
  • The year over year net income to common stockholders growth rate now stands at -20.93%.
Over the past 15 months, CLDX's revenue has gone down $7,540,000.

The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.078 -96.493 -105.986
2022-06-30 0.824 -77.673 -99.654
2022-03-31 4.141 -67.359 -77.023
2021-12-31 4.651 -60.909 -70.511
2021-09-30 8.103 -51.597 -72.263
2021-06-30 8.618 -47.086 -66.035

CLDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLDX has a Quality Grade of D, ranking ahead of 19.92% of graded US stocks.
  • CLDX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
  • CALA, CYRX, and BDSI are the stocks whose asset turnover ratios are most correlated with CLDX.

The table below shows CLDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 1 -0.480
2021-03-31 0.022 1 -0.447
2020-12-31 0.034 1 -0.479
2020-09-30 0.024 1 -0.470
2020-06-30 0.028 1 -0.636
2020-03-31 0.038 1 -0.864

CLDX Price Target

For more insight on analysts targets of CLDX, see our CLDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $64.83 Average Broker Recommendation 1.25 (Strong Buy)

Celldex Therapeutics Inc. (CLDX) Company Bio

Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.

CLDX Latest News Stream

Event/Time News Detail
Loading, please wait...

CLDX Latest Social Stream

Loading social stream, please wait...

View Full CLDX Social Stream

Latest CLDX News From Around the Web

Below are the latest news stories about CELLDEX THERAPEUTICS INC that investors may wish to consider to help them evaluate CLDX as an investment opportunity.

Wells Fargo starts Celldex at underweight, cites over-optimism for hives drug

More on Celldex

AppLovin upgraded, Genpact downgraded: Wall Street's top analyst calls

AppLovin upgraded, Genpact downgraded: Wall Street's top analyst calls

Yahoo | August 22, 2023

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 8, 2023

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

- Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 -- First patient dosed in Phase 2 EoE study - HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Last month, we announced that enrollment in our Phase 2 chronic spontaneous urticaria trial was completed well ahead of schedule, exceeding projections by nearly

Yahoo | August 8, 2023

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. CSU is

Yahoo | July 11, 2023

Read More 'CLDX' Stories Here

CLDX Price Returns

1-mo -9.92%
3-mo -26.06%
6-mo -28.23%
1-year -8.83%
3-year 110.76%
5-year 311.61%
YTD -41.13%
2022 15.35%
2021 120.55%
2020 685.65%
2019 -25.67%
2018 -92.96%

Continue Researching CLDX

Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:

Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!